Screener
Immix Biopharma, Inc. IMMX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-021764
| Line item | 2026 / For the Three Months Ended / March 31, | 2025 / For the Three Months Ended / March 31, |
|---|---|---|
| General and administrative expenses | $4,823,378 | $2,707,851 |
| Research and development | 5,980,477 | 1,975,074 |
| Total operating expenses | 10,803,855 | 4,682,925 |
| Loss from operations | (10,803,855) | (4,682,925) |
| Other income (expense): | ||
| Interest income | 717,168 | 150,219 |
| Total other income (expense), net | 717,168 | 150,219 |
| Loss before provision for income taxes | (10,086,687) | (4,532,706) |
Document
FAQ
- What is Immix Biopharma, Inc.'s operating income?
- Immix Biopharma, Inc. (IMMX) reported operating income of -$10.8M in Q1 2026.
- How has Immix Biopharma, Inc.'s operating income changed year-over-year?
- Immix Biopharma, Inc.'s operating income decreased by 130.7% year-over-year, from -$4.68M to -$10.8M.
- What is the long-term trend for Immix Biopharma, Inc.'s operating income?
- Over 4 years (2021 to 2025), Immix Biopharma, Inc.'s operating income has grown at a 117.0% compound annual growth rate (CAGR), from -$1.35M to -$29.96M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Immix Biopharma, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude